Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the 2013 Deutsche Bank BioFEST conference being held December 2-3, 2013 at the Four Seasons Hotel in Boston, MA. On Monday, December 2 at 4:00 PM (ET), Burt Adelman M.D., Chief Medical Officer, and George Migausky, Chief Financial Officer, will participate in a fireside chat to discuss the Company’s key value drivers – the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Program.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The webcast will also be available on the Dyax website for a limited period of time following the conference.
Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR ® (ecallantide) business, DX-2930 and the Licensing and Funded Research Program (LFRP).Dyax developed KALBITOR on its own and, since February 2010, has been selling it in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval and commercialize KALBITOR in certain markets and is evaluating opportunities in others. The Company is developing products to expand its angioedema portfolio, including a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE and a biomarker assay to identify plasma- kallikrein-mediated disorders. In August 2013, Dyax began a Phase 1 clinical study evaluating the safety and tolerability of single subcutaneous administration of DX-2930 in healthy subjects. KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 revenue eligible product candidates in various stages of clinical development, including three in Phase 3 trials.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts